Semaglutide and Heart Outcomes: Reading the SELECT Trial

Semaglutide research is often discussed in terms of weight loss, but SELECT asked a different question: could treatment reduce major cardiovascular events in people with established cardiovascular disease, overweight or obesity, and no diabetes? The distinction matters because a change on a weighing scale is not itself proof that fewer heart attacks or strokes will occur. SELECT measured clinical events directly. [1]

Who took part, and what counted as an outcome?

The randomised, double-blind trial enrolled 17,604 adults aged at least 45, with a body-mass index of at least 27 and pre-existing cardiovascular disease. Participants received the trial semaglutide preparation or placebo. Its primary endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke, analysed as time to the first qualifying event. Average follow-up was 39.8 months. [1]

A primary event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The reported hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90. This supported a cardiovascular benefit in the studied population. It did not test whether otherwise healthy people should take semaglutide to prevent their first cardiovascular disease diagnosis. [1]

Relative benefit and absolute benefit answer different questions

The headline description of a 20% reduction refers to the relative hazard comparison. Subtracting the reported event proportions gives an absolute difference of approximately 1.5 percentage points during the trial. These two descriptions are compatible; they simply describe the findings on different scales. [1]

For interpretation, the important habit is to retain the baseline risk and follow-up period alongside a relative percentage. The same relative effect would correspond to a different absolute benefit in a population with a different underlying event rate. Extrapolating beyond the enrolled population requires additional evidence, not just reuse of the headline number.

Did starting blood glucose explain the result?

A prespecified SELECT analysis examined cardiovascular outcomes across baseline HbA1c groups and changes in HbA1c. HbA1c is a measure of longer-term glucose exposure. The investigators did not find evidence that cardiovascular risk reduction differed across the baseline groups; results were also consistent across categories of HbA1c change. [2]

That supports the relevance of the findings beyond people with higher starting HbA1c within this trial. It does not identify every mechanism responsible for benefit. The analysis uses the SELECT participants again, so it should not be counted as a second independent cardiovascular-outcomes trial. [2]

Weight change provides context, not a complete mechanism

Another prespecified analysis examined weight and body measurements over longer follow-up. At 208 weeks, the reported mean weight changes were −10.2% with semaglutide and −1.5% with placebo. Weight loss was sustained over the observed four-year period. [3]

These findings describe an additional outcome from the same research programme. Observing both weight loss and fewer cardiovascular events does not, on its own, determine exactly how much of the cardiovascular benefit was caused by weight change rather than other effects. A careful explanation keeps that mechanistic uncertainty visible.

Benefits must be read alongside tolerability

In the main trial, adverse events led to permanent treatment discontinuation in 16.6% of semaglutide participants versus 8.2% of placebo participants. The trial was funded by Novo Nordisk. Both details belong alongside the efficacy result when considering its practical interpretation. [1]

The FDA added a cardiovascular-risk-reduction indication for Wegovy injection in March 2024 for adults with cardiovascular disease and overweight or obesity. Its announcement notes that participants also received usual cardiovascular care and lifestyle counselling. The medicine was studied as an addition to care, not a replacement for managing other risk factors. [4]

The same FDA announcement identifies gastrointestinal adverse effects, warnings involving pancreatitis and gallbladder disease, and a boxed warning concerning thyroid C-cell tumours. It also describes contraindications involving medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. These are examples of why clinical suitability requires current prescribing information and an individual medical assessment. [4]

What this means for research readers

SELECT provides evidence about a defined pharmaceutical intervention and population. It cannot establish that every semaglutide-labelled research material is clinically equivalent, or that approval of a particular medicine extends to research vials or every jurisdiction.

Bali Peptide Lab is a commercial research-product supplier. This article is an educational discussion of clinical literature, not a recommendation for personal treatment or administration. Reading the comparator, endpoint, absolute effect and safety findings together gives a more useful picture than interpreting weight-loss or cardiovascular headlines alone.